<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34190">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661503</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1762</org_study_id>
    <secondary_id>2014-005130-55</secondary_id>
    <nct_id>NCT02661503</nct_id>
  </id_info>
  <brief_title>HD21 for Advanced Stages</brief_title>
  <official_title>HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of
      BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to
      PET-positive residual lesions â‰¥2.5 cm, in terms of progression free survival (efficacy
      objective).

      If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate
      reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment
      measured by treatment related morbidity (TRMorbidity objective).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Related Morbidity</measure>
    <time_frame>during 6 cycles of chemotherapy (21-day cycles)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>BEACOPP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Cytarabine (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRECADD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Cytarabine (A) Dacarbazine (D) Dexamethasone (D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>BEACOPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>BRECADD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven classical Hodgkin lymphoma

          -  First diagnosis, no previous treatment, 18 to 60 years of age

          -  Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV

        Exclusion Criteria:

          -  Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma

          -  Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix uteri,
             completely resected melanoma TNMpT1)

          -  Prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Borchmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne, I. Dept. of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fuchs</last_name>
    <email>ghsg@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Borchmann, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 17, 2016</lastchanged_date>
  <firstreceived_date>January 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Borchmann</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
